At present, medications of the GLP‐1RA class, such as liraglutide 3.0 mg,27 semaglutide 2.4 mg,28 and tirzepatide (GLP‐1/GIP [glucose‐dependent insulinotropic polypeptide] agonist)29 have been approved for weight management for adult patients with obesity or overweight with obesity‐related complications. Here, GIP is linked to Obesity.